featured
Durvalumab With or Without Tremelimumab Plus Chemotherapy as First-Line Therapy for Metastatic NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
J. Clin. Oncol 2022 Nov 03;[EPub Ahead of Print], ML Johnson, BC Cho, A Luft, J Alatorre-Alexander, SL Geater, K Laktionov, SW Kim, G Ursol, M Hussein, FL Lim, CT Yang, LH Araujo, H Saito, N Reinmuth, X Shi, L Poole, S Peters, EB Garon, T MokFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.